Unity Biotechnology Names Federico Grossi Chief Medical Officer, Pre-market Stock Rises

(RTTNews) - Shares of Unity Biotechnology, Inc. (UBX) are gaining 9% in the pre-market trading after it has announced the appointment of Federico Grossi as Chief Medical Officer.

Federico Grossi said he is looking forward to advance UBX1325, and advance pipeline to provide new and differentiated treatment options for patients with progressive retinal diseases. Grossi has 20 years of experience, with rich expertise in ophthalmology.

Grossi had previously served as Chief Medical Officer at Apellis Pharmaceuticals.

Friday, UBX had closed 12.28% higher at $1.28 on the Nasdaq. In the pre-market trading, UBX is 8.59% further higher at $1.39.